Latigo Biotherapeutics priced its upsized $345.6 million IPO on August 6, 2026, at $18 per share after initially targeting a $1.08 billion valuation with shares at $16–18, producing an estimated closing market capitalization near $1.14 billion. Strong institutional demand, supported by positive Phase 2 data for its Nav1.8 inhibitor LTG-001 and a favorable biotech IPO window, drove the upsizing and alignment with the $1.15–1.3 billion range. Trader consensus reflects the skin-in-the-game pricing outcome and recent share gains above $21 on debut. Potential challenges include sharp post-IPO volatility from broader market sentiment shifts, clinical setbacks in planned Phase 3 trials, or dilution from future capital raises that could pressure the realized capitalization below this band.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日11億5,000万ドル～13億ドル 100.0%
13億ドル～14.5億ドル 1.9%
14億5000万ドル以上 1.9%
10億ドル～11.5億ドル <1%
$1,974 Vol.
$1,974 Vol.
2026/08/07
8億5,000万ドル未満
いいえ
8億5千万ドル〜10億ドル
いいえ
10億ドル～11.5億ドル
いいえ
11億5,000万ドル～13億ドル
はい
13億ドル～14.5億ドル
いいえ
14億5000万ドル以上
いいえ
2026年10月以前にIPOなし
いいえ
11億5,000万ドル～13億ドル 100.0%
13億ドル～14.5億ドル 1.9%
14億5000万ドル以上 1.9%
10億ドル～11.5億ドル <1%
$1,974 Vol.
$1,974 Vol.
2026/08/07
8億5,000万ドル未満
$351 Vol.
いいえ
8億5千万ドル〜10億ドル
$436 Vol.
いいえ
10億ドル～11.5億ドル
$193 Vol.
いいえ
11億5,000万ドル～13億ドル
$250 Vol.
はい
13億ドル～14.5億ドル
$150 Vol.
いいえ
14億5000万ドル以上
$180 Vol.
いいえ
2026年10月以前にIPOなし
$414 Vol.
いいえ
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Latigo Biotherapeutics priced its upsized $345.6 million IPO on August 6, 2026, at $18 per share after initially targeting a $1.08 billion valuation with shares at $16–18, producing an estimated closing market capitalization near $1.14 billion. Strong institutional demand, supported by positive Phase 2 data for its Nav1.8 inhibitor LTG-001 and a favorable biotech IPO window, drove the upsizing and alignment with the $1.15–1.3 billion range. Trader consensus reflects the skin-in-the-game pricing outcome and recent share gains above $21 on debut. Potential challenges include sharp post-IPO volatility from broader market sentiment shifts, clinical setbacks in planned Phase 3 trials, or dilution from future capital raises that could pressure the realized capitalization below this band.
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
マーケット開始日： Aug 5, 2026, 5:52 AM ET
音量
$1,974終了日
2026/08/07マーケット開始日
Aug 5, 2026, 5:52 AM ETResolver
0x69c47De9D...提案された結果: いいえ
異議申し立てなし
最終結果: いいえ
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Latigo Biotherapeutics priced its upsized $345.6 million IPO on August 6, 2026, at $18 per share after initially targeting a $1.08 billion valuation with shares at $16–18, producing an estimated closing market capitalization near $1.14 billion. Strong institutional demand, supported by positive Phase 2 data for its Nav1.8 inhibitor LTG-001 and a favorable biotech IPO window, drove the upsizing and alignment with the $1.15–1.3 billion range. Trader consensus reflects the skin-in-the-game pricing outcome and recent share gains above $21 on debut. Potential challenges include sharp post-IPO volatility from broader market sentiment shifts, clinical setbacks in planned Phase 3 trials, or dilution from future capital raises that could pressure the realized capitalization below this band.
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
音量
$1,974終了日
2026/08/07マーケット開始日
Aug 5, 2026, 5:52 AM ETResolver
0x69c47De9D...提案された結果: いいえ
異議申し立てなし
最終結果: いいえ
Latigo Biotherapeutics priced its upsized $345.6 million IPO on August 6, 2026, at $18 per share after initially targeting a $1.08 billion valuation with shares at $16–18, producing an estimated closing market capitalization near $1.14 billion. Strong institutional demand, supported by positive Phase 2 data for its Nav1.8 inhibitor LTG-001 and a favorable biotech IPO window, drove the upsizing and alignment with the $1.15–1.3 billion range. Trader consensus reflects the skin-in-the-game pricing outcome and recent share gains above $21 on debut. Potential challenges include sharp post-IPO volatility from broader market sentiment shifts, clinical setbacks in planned Phase 3 trials, or dilution from future capital raises that could pressure the realized capitalization below this band.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問